02616 CSTONE PHARMA-B
- 1.200
- +0.010+0.84%
CSTONE PHARMA-B News
CSTONE PHARMA-B: INSIDE INFORMATION ANNOUNCEMENT - CSTONE ANNOUNCES EUROPEAN COMMISSION APPROVAL OF SUGEMALIMAB (CEJEMLY) AS FIRST-LINE TREATMENT FOR NON-SMALL CELL LUNG CANCER
CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2024
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE AND HENGRUI ENTER INTO AN EXCLUSIVE PROMOTION AGREEMENT OF AYVAKIT (AVAPRITINIB TABLETS) IN MAINLAND CHINA
CSTONE PHARMA-B: CHANGE OF JOINT COMPANY SECRETARY, PROCESS AGENT AND AUTHORIZED REPRESENTATIVE AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
CSTONE PHARMA-B: SIXTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
CSTONE PHARMA-B: POLL RESULTS OF ANNUAL GENERAL MEETINGHELD ON JUNE 18, 2024ANDAMENDMENTS TO THE ARTICLES OFASSOCIATION
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES APPROVAL OF MANUFACTURING LOCALIZATION REGISTRATION APPLICATION FOR AYVAKIT (AVAPRITINIB TABLETS) BY CHINA NMPA
CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2024
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES PRESENTATION OF LATEST FIRST-IN-HUMAN DATA FOR CS5001 (ROR1 ADC) AT ASCO 2024
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CHMP OF THE EUROPEAN MEDICINE AGENCY RECOMMENDS APPROVALOF CEJEMLY (SUGEMALIMAB, ANTI-PD-L1) AS FIRST-LINE TREATMENT FOR NSCLC
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE AND EWOPHARMA ENTER INTO STRATEGIC PARTNERSHIP FOR SUGEMALIMAB IN CENTRAL EASTERN EUROPE AND SWITZERLAND
CSTONE PHARMA-B: FORM OF PROXY FOR ANNUAL GENERAL MEETING
CSTONE PHARMA-B: NOTICE OF ANNUAL GENERAL MEETING
CSTONE PHARMA-B: PROPOSALS FOR GENERAL MANDATES TO ISSUEAND BUY BACK SHARES,RE-ELECTION OF RETIRING DIRECTORS,RE-APPOINTMENT OF AUDITOR,PROPOSED ADOPTION OFTHE SIXTH AMENDED AND RESTATEDARTICLES OF ASSOCIATION,PROPOSED GRANT OF SHARE OPTIONSAND RSUS TO A DIRECTORA
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES ABSTRACT RELEASE OF CS5001 (ROR1 ADC) FIRST-IN-HUMAN CLINICAL DATA ON ASCO WEBSITE
CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2024
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE TO PRESENT CS5001 (ROR1 ADC) PHASE I RESULTS AT 2024 ASCO ANNUAL MEETING
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY NON-EXECUTIVE DIRECTOR MR. KENNETH WALTON HITCHNER III BY 2,219,500 SHARES
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTOR DR. JIANXIN YANG BY 3,345,000 SHARES,WITH ACCUMULATED PURCHASE TOTALLING 7,529,500 SHARES
CSTONE PHARMA-B: ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2023
Analysis
Price Target
No Data
